Howard Sheppard
Directeur/Membre du Conseil chez H. Sheppard Ltd.
Profil
Howard Sheppard is currently a Director at H.
Sheppard Ltd.
He previously worked as a Financial Controller at Senexis Ltd.
from 2012 to 2013.
Postes actifs de Howard Sheppard
| Sociétés | Poste | Début |
|---|---|---|
| H. Sheppard Ltd. | Directeur/Membre du Conseil | 01/06/2011 |
Anciens postes connus de Howard Sheppard
| Sociétés | Poste | Fin |
|---|---|---|
Senexis Ltd.
 Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | Comptroller/Controller/Auditor | 17/07/2013 |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | Health Technology |
| H. Sheppard Ltd. |
